Results 81 to 90 of about 18,490 (188)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. [PDF]

Front Immunol
Bielski P, Barczyński J, Mikitiuk M, Myrcha M, Rykała K, Boon L, Gąsior W, Hec-Gałązka A, Holak TA, Sitar T.   +9 more
europepmc   +1 more source

Research Advice for Early Career Transplant Infectious Disease Clinicians

Transplant Infectious Disease, EarlyView.
ABSTRACT As part of an ongoing series of social media discussions, the Transplant Infectious Diseases Early Career Network hosted an open forum for the transplant infectious disease community to discuss the development of research careers for junior faculty. Topics discussed included opportunities for research, identifying potential research questions,
Rebecca N. Kumar, Michael J. Scolarici, Chelsea Gorsline, Lara Danziger‐Isakov, John Baddley, Courtney E. Harris   +5 more
wiley   +1 more source

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies. [PDF]

Front Pharmacol
Xu Y, Yang S, Rao Q, Gao Y, Zhou G, Zhao D, Shi X, Chai Y, Zhao C.   +8 more
europepmc   +1 more source

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

The physiological limits of bispecific monoclonal antibody tissue targeting specificity. [PDF]

MAbs
Sepp A, Stader F, Derbalah A, Liu C, Zyla A, Gardner I, Jamei M.   +6 more
europepmc   +1 more source

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients

European Journal of Haematology, Volume 115, Issue 1, Page 16-28, July 2025.
ABSTRACT Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated the prognostic and predictive significance of 1q gain [gain(1q)] and amplification [ampl(1q)] in 635 RRMM patients treated with daratumumab‐, elotuzumab‐, and carfilzomib‐based triplet regimens ...
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, Massimo Offidani, Renato Zambello, Sara Bringhen, Nicola Giuliani, Catello Califano, Marino Brunori, Alfredo Gagliardi, Nicola Sgherza, Angela Maria Quinto, Gregorio Barilà, Angelo Belotti, Claudio Cerchione, Gloria Margiotta Casaluci, Raffaele Fontana, Velia Bongarzoni, Giuseppe Tarantini, Daniele Derudas, Francesca Patriarca, Alessandro Gozzetti, Adelina Sementa, Elisabetta Antonioli, Angela Rago, Flavia Lotti, Claudio De Magistris, Maria Teresa Petrucci, Loredana Pettine, Niccolò Bolli, Concetta Conticello, Elena Zamagni, Salvatore Palmieri, Maurizio Musso, Anna Mele, Roberta Della Pepa, Ernesto Vigna, Antonella Bruzzese, Francesca Fazio, Roberto Mina, Laura Paris, Iolanda Donatella Vincelli, Giuliana Farina, Clotilde Cangialosi, Katia Mancuso, Antonietta Pia Falcone, Giuseppe Mele, Antonello Sica, Sonia Morè, Giovanni Reddiconto, Giovanni Tripepi, Graziella D'Arrigo, Emiliano Barbieri, Micol Quaresima, Claudio Salvatore Cartia, Sara Pezzatti, Magda Marcatti, Francesca Farina, Anna Cafro, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Silvia Mangiacavalli, Massimo Gentile   +66 more
wiley   +1 more source

Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening. [PDF]

MAbs
Metcalf KJ, Wo G, Zaragoza JP, Raoufi F, Baker J, Chen D, Derebe M, Hogan J, Hsu A, Kofman E, Leigh D, Li M, Malashock D, Mann C, Motlagh S, Park J, Sathiyamoorthy K, Shidhore M, Tang Y, Teng K, Williams K, Waight A, Yilmaz S, Zhang F, Zhong H, Fayadat-Dilman L, Bailly M.   +26 more
europepmc   +1 more source

TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Insights from the bottom-up development of LGR5-targeting immunotherapeutics. [PDF]

Immunother Adv
Mueller N, de la Roche MA, de la Roche M.   +2 more
europepmc   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

American Journal of Hematology, Volume 100, Issue 6, Page 998-1009, June 2025.
ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamara   +13 more
wiley   +1 more source